Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002171 · ClinicalTrials.gov registry record · Phase 2
A Study of Viracept in HIV-Positive Women
A Phase 2 study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002171: Completed Phase 2 study, sponsored by Agouron Pharmaceuticals.
NCT00002171 is a Phase 2 study that has completed, run by Agouron Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002171, a Phase 2 study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count \<= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.
Interventions
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00002171 record still lists
NCT00002171 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir mesylate is the first listed.
NCT00002171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002171 about?
NCT00002171 is a clinical study titled "A Study of Viracept in HIV-Positive Women". The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count \<= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.
What is the current status of trial NCT00002171?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002171?
The interventions under investigation include: Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002171?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.